Anti-VEGFtherapyforneovascularoculardiseasesCiullaandRosenfeld167
Table1Characterizationofneovascularoculardiseasesotherthanage-relatedmaculardegenerationOculardiseasePDR
NeovascularcharacteristicsRetinaoririsneovascularization;activeCNVleakage[12 ];DME[1 ];NVG[13–15]CentralRVO,hemicentralRVO,orbranchRVOwithischemicornonischemicobstructionbythrombosisorexternalcompression[18];
neovascularization[19];macularedema[20–22];NVG[13]
CNV;retinaldetachment
AffectedpopulationLeadingcauseofblindnessamongUSworkingpopulation
(20–74yearsold)Allages;however,51% rstdiagnosedat65yearsorolder[23]
AssociatedriskfactorsChronichyperglycemia[16]
Prevalence
4.1millioninUSA;900000inUSAwithvision-threateningdisease[17]
1.6%incidenceinUSpopulationover50yearsold[3,24]
RVO
Age;highbloodpressure;atheroscleroticdiseaseinretinalveins[24]
ROP
PathologicmyopiaCNV
AngioidstreaksCNV
PresumedocularhistoplasmosissyndromeRegressedCNVmembranes; brovasculardisciformscar[29]
IdiopathicpolypoidalCNV;detachmentofsensorychoroidalretinainthemacula[30,31]vasculopathyNVG
Angleclosuresecondarytoa brovascularmembraneinanteriorchamberduetoretinalischemiaandangiogenesis;ischemiccentralRVOin
58–86%ofaffectedeyes[33]
Lowgestationalage;lowbirthweight;useofsupplementaloxygentherapy;white[25]
Signi cantcauseofabnormalLacquercracksintheneovascularizationandvisionstretchingretinalossinyoungerUSpopulation(woundrepair)[27](under50yearsold)
Signi cantcauseofabnormalCrackeddisruptionsofneovascularizationandvisiontheelasticlayeroflossinyoungerUSpopulationBruch’smembrane(under50yearsold)(woundrepair)[17,28]Signi cantcauseofabnormalInfectionwithHistoplasmaneovascularizationandvisioncapsulatumlossinyoungerUSpopulation(under50yearsold)
Signi cantcauseofabnormalPigmentedrace;intraocularneovascularizationandvisionin ammation[32]lossinyoungerUSpopulation(under50yearsold)
Over40yearsold;maydevelopDiabetesevenwithoutin33–64%ofeyeswithPDR;impairedrenaluntreatedPDRfunction;
hypoalbuminemia[34]
Infants(lifelongeffects);
leadingcauseofblindnessinprematureneonates50–65%ofinfantsweighing 1250g[25,26]NA
NA
NA
NA
NA
CNV,choroidalneovascularization;DME,diabeticmacularedema;NA,notavailable;NVG,neovascularglaucoma;PDR,proliferativediabeticretinopathy;RAP,retinalangiomatousproliferation;ROP,retinopathyofprematurity;RPE,retinalpigmentepithelium;RVO,retinalveinocclusion.
Diabeticretinopathyanddiabeticmacularedema
Ocularmicrovascularcomplicationsaffectalmostallpatientswithtype1diabetesandatleast60%ofpatientswithtype2diabetes[35].Increasedpatientlongevity,alongwithincreasedobesity,hasledtoanincreasedprevalenceoftype2diabetes-associateddiabeticretino-pathy,whichistheleadingcauseofblindnessinthe
workingpopulation(age20–74years)indevelopedcountries[2].Visuallossmayoccurfromneovasculariza-tion,asinPDR,orfromincreasedretinalvascularper-meabilityleadingtodiffuseleakagefromcapillarywalls,focalleakagefrommicroaneurysms,andaccumulationof uidandmacromoleculesintheretina,asinDME[2,36,37].Theseconditionsarecharacterizedbyreduced
Table2Anti-vascularendothelialgrowthfactoragentscurrentlyavailableorindevelopmentforthetreatmentofneurovasculareyediseasesotherthanage-relatedmaculardegenerationAgent
Pegaptanib(Macugen)Ranibizumab(Lucentis)Bevacizumab(Avastin)VEGFtrap
Triamcinoloneacetonide(Kenalog-40)Bevasiranib(Cand5)
AGN211745(Sirna-027)Pazopanib
Class
Aptamer
MonoclonalantibodyfragmentMonoclonalantibodyDecoyreceptorCorticosteroid
siRNAsiRNA
Tyrosinekinaseinhibitor
Moleculartarget
VEGF165isoformAllVEGF-AisoformsAllVEGF-Aisoforms
AllVEGF-AisoformsandPlGFAntiangiogenic;speci ctargets
unknown,possiblyVEGFandothersVEGF-AmRNAVEGF-R1mRNA
InhibitionofVEGFReceptor1,2,and3tyrosinekinases
ManufacturerOSI/EyetechGenentechGenentechaRegeneron
Bristol-MyersSquibbOPKOHealthAllergan
GlaxoSmithKline
PlGF,placentalgrowthfactor;VEGF,vascularendothelialgrowthfactor.a
InvestigationsoftheclinicaluseofbevacizumabinoculardiseasesareindependentofGenentech.
therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and ...
anti-vascular endothelial growth factor (VEGF) ...found in human plasma and serum and ocular ...(Avastin) therapy for neovascular age-related ...
anti-vascular endothelial growth factor therapy – bevacizumab Acta Ophthalmol....It has been known that ocular diseases in which in?ammatory and autoimmune...
therapy or having an accompanying ocular disease. ...therapy for neovascular age - related macular ... an anti-vascular endothelial growth factor antigen...
(Macugen ) TM 1 The Impact of Neovascular AMD ...Injection – First Anti-VEGF Therapy for the Eye...Vascular Endothelial Growth Factor (VEGF) Vascular ...
anti-vascular endothelial growth factor fusion ...Thus, with one injection of KH902, neovascular ...Both of them could inhibit the ocular ...
anti-vascular endothelial growth factor fusion ...Thus, with one injection of KH902, neovascular ...Both of them could inhibit the ocular ...
热门文档